FTC Blocks Edwards Lifesciences' $945M JenaValve Acquisition Over TAVR-AR Device Competition Concerns
核心洞察
The Federal Trade Commission (搜索) moved to block Edwards Lifesciences (搜索)' proposed $945 million acquisition of JenaValve Technology (搜索), citing concerns that the deal would eliminate competition in the transcatheter aortic valve (搜索) replacement device market for aortic regurgitation (搜索).
Edwards executed agreements to acquire both JenaValve and JC Medical (搜索) within two days in July 2024, combining the only two companies with ongoing U.S. clinical trials for TAVR-AR devices to treat the potentially fatal heart condition.
More than 8 million Americans suffer from aortic regurgitation (搜索), and JenaValve's Trilogy (搜索) device is poised to become the first TAVR-AR device to reach the U.S. commercial market.
The Federal Trade Commission (搜索) has moved to block Edwards Lifesciences (搜索) Corp.'s proposed $945 million acquisition of JenaValve Technology (搜索), Inc., alleging that the deal would eliminate competition in the emerging market for transcatheter aortic valve (搜索) replacement devices designed to treat aortic regurgitation (搜索) (TAVR-AR devices).
The FTC's complaint centers on Edwards' dual acquisition strategy executed over two days in July 2024, when the company signed agreements to acquire both JenaValve and JC Medical (搜索), the two leading companies competing to bring TAVR-AR devices to market. Edwards completed its acquisition of JC Medical in August 2024, and the proposed JenaValve acquisition would combine the only two companies with ongoing clinical trials in the United States for TAVR-AR devices.
Market Impact and Patient Population
More than 8 million Americans suffer from aortic regurgitation (搜索), a potentially fatal heart condition that occurs when the heart's aortic valve (搜索) does not close properly, causing blood to backflow into the heart. Currently, surgical valve replacement via open heart surgery is the only FDA-approved procedure to treat aortic regurgitation, making TAVR-AR devices a significant advancement as they offer a new and less invasive treatment option.
JenaValve is positioned to become the first company to bring a TAVR-AR device, called Trilogy (搜索), to the commercial market in the United States. According to the FTC, FDA approval or commercialization of any other TAVR-AR device by another company, aside from Edwards and JenaValve, is not expected for the foreseeable future.
Competition Concerns
"Edwards' attempt to buy the U.S. market for TAVR-AR devices would eliminate the head-to-head competition that has spurred innovation for lifesaving artificial heart valves," said Daniel Guarnera, Director of the FTC's Bureau of Competition. "The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards' JC Medical (搜索) subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs."
The FTC alleges that direct head-to-head competition between Edwards, through its now-subsidiary JC Medical (搜索), and JenaValve has driven both companies to accelerate the development of their TAVR-AR devices. The agency argues that patients will benefit if JenaValve and Edwards continue to compete directly to complete their separate TAVR-AR device clinical trials, product improvements, and commercialization plans.
Legal Proceedings and Company Response
The Commission voted 3-0 to issue an administrative complaint and authorize staff to seek a temporary restraining order and a preliminary injunction. The federal court complaint and request for preliminary relief was filed in the U.S. District Court for the District of Columbia to halt the transaction pending an administrative proceeding.
Edwards disagreed with the FTC's decision, arguing that it will limit treatment options for patients with aortic regurgitation (搜索). The company contended that the acquisition will actually "accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR." Edwards plans to continue pursuing regulatory approval for the deal and expects a final determination by the end of the first quarter of 2026.
JenaValve also expressed commitment to completing the transaction, stating confidence in the merger rationale and the value it will bring to patients. The company intends to join Edwards in defending the case in court.
Financial Impact
In response to the FTC's action, Edwards increased its forecast for 2025 adjusted earnings per share to the high end of a range of $2.45 to $2.55, up from the high end of a range of $2.40 to $2.50. The company noted there is no impact to revenue guidance.
The FTC noted that Edwards has not been willing to engage on divesting JC Medical (搜索) to resolve the competition concerns with the proposed JenaValve acquisition, with the competition concerns specifically predicated on Edwards owning both JenaValve and JC Medical simultaneously.